The ILLUMINATE Trial
Effects of Torcetrapib in Patients at High Risk for Coronary Events.
EAS 2012, the 80th European Atherosclerosis Society Congress, offers an exciting combination of high-level scientific learning from world experts with a change to experience the cultural hub of Milan.
This event will take place from may 25-28 in Milan.
Visit the website and subscribe.